Ignite Creation Date:
2024-05-06 @ 8:07 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06251895
Status:
COMPLETED
Last Update Posted:
2024-02-09
First Post:
2024-01-23
Brief Title:
Association of Systemic Immune-inflammation Index and Severity of Diabetic Ketoacidosis in Type 1 Diabetes Mellitus
Sponsor:
Jahra Hospital
Organization:
Jahra Hospital
Study Overview
Official Title:
Association of the Systemic Immune-inflammation Index SII and Severity of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Mellitus A Retrospective Cohort Study
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Diabetic ketoacidosis DKA is the most serious metabolic complication of type 1 diabetes mellitus T1DM Insulin deficiency and inflammation play a role in the pathogenesis of DKA The investigators aim to assess the systemic immune-inflammation index SII as a marker of severity among T1DM patients with DKA and without infection
Detailed Description:
Diabetic ketoacidosis DKA is one of the most severe acute metabolic complications of diabetes mellitus DM Therefore DKA patients require prompt treatment and any delay in identifying severe DKA cases can lead to worse outcomes DKA provokes a systemic inflammatory response through increased levels of various cytokines such as interleukin IL-8 IL-6 IL-10 tumor necrosis factor-alpha TNF-α and IL-1B This will lead to cellular activation cellular adhesion increased oxidative stress and endothelial damage possibly contributing to complications Consequently surrogate markers of inflammation and immune status may help in the early identification of patients with severe DKA
The systemic immune-inflammation index SII had a better prognostic value compared to NLR and PLR among cancer patients Recently studies have suggested a link between SII and increased risk of atherosclerotic cardiovascular disease ASCVD hepatic steatosis and worse outcomes among hypertensive patients and patients with stroke
Therefore the investigators aim to examine SII as a marker of severity in T1DM patients with DKA in an uninfected state
The systemic immune-inflammation index SII had a better prognostic value compared to NLR and PLR among cancer patients Recently studies have suggested a link between SII and increased risk of atherosclerotic cardiovascular disease ASCVD hepatic steatosis and worse outcomes among hypertensive patients and patients with stroke
Therefore the investigators aim to examine SII as a marker of severity in T1DM patients with DKA in an uninfected state
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None